The breakthrough in CD30-targeted therapy in HL came with the development of brentuximab vedotin (SGN-35), an ADC consisting of chimeric CD30 mAb brentuximab (cAC10) and an antimitotic agent monomethyl auristatin E (MMAE) (Table 1). The gene discussed is TNFRSF8; the disease is Hodgkins lymphoma.